Information on the target
Cairo, Egypt – March 2025 – A consortium of investors led by SPE Capital (SPE), through its Private Equity Fund III (PEF III), has successfully closed its investment in Orchidia Pharmaceutical Industries S.A.E. This company is recognized as a leading ophthalmic pharmaceutical manufacturer operating in Egypt and throughout the Middle East and Africa. Founded in 1993 by Dr. Ossama Abbas, Orchidia has established a strong market presence, exporting nearly 100 registered eye care products to over 20 countries, utilizing advanced Blow-Fill-Seal technology. Notably, Orchidia was the first company in Egypt to introduce single-dose unit forms for its products.
This transaction marks the second partnership between SPE Capital and the Abbas family, building on a successful previous investment from 2013 to 2017 that significantly enhanced Orchidia's market position and export capabilities. The current investment signifies a renewal of this longstanding collaboration, combining SPE’s operational expertise with the backing of three prominent development finance institutions, while ensuring continuity in leadership with the Abbas family at the helm.
Industry overview in the target’s specific country
The pharmaceutical industry in Egypt is experiencing robust growth, driven by increasing healthcare demands and a rising population. With a strategic location that serves as a gateway to both African and Middle Eastern markets, Egypt is well-positioned to become a regional hub for pharmaceutical manufacturing and distribution. The government has implemented various reforms aimed at enhancing the pharmaceutical sector, including regulatory improvements and incentives for local production.
Moreover, the Egyptian pharmaceutical market is characterized by a growing demand for high-quality, affordable medicines, particularly in the ophthalmic segment. As the prevalence of eye-related disorders rises, the need for innovative and accessible treatment options becomes increasingly critical. This trend presents significant opportunities for companies like Orchidia, which are dedicated to providing specialized ophthalmic products.
In addition, the involvement of development finance institutions such as EBRD, Proparco, and BIO underscores the potential for impactful investments in the sector. These institutions are committed to fostering sustainable economic growth and improving healthcare access, which aligns with Orchidia's mission to enhance the quality of life for patients across the region.
Overall, the Egyptian pharmaceutical industry is poised for continued expansion, supported by favorable demographics, government initiatives, and a…